This is an automatically translated article.
Regofa 1 drug is used to treat chronic hepatitis B virus infection in adults with the main ingredient Entecavir. The following article would like to send readers detailed information about the drug line Regofa 1.
1. Indications for taking Regofa 1
Regofa 1 drug has the main ingredient Entecavir (as Entecavir monohydrate 1.06 mg) 1 mg and other excipients in the drug.
Regofa 1 is used in the treatment of chronic hepatitis B virus infection in adults with evidence of viral replication activity, tissue active disease, or persistent elevations in serum aminotransferases. bar.
Regofa 1 drug should not be used in case of patients with hypersensitivity, history of allergy to entecavir or to any of its ingredients.
2. Dosage - How to take Regofa 1
Regofa 1 should be taken on an empty stomach and taken at least 2 hours after a meal and 2 hours before the next meal.
Recommended dose of Regofa 1 for adults and adolescents >16 years of age with chronic hepatitis B virus infection and not taking nucleosides: 0.5mg Entecavir once daily.
Recommended dose of Regofa 1 for adults and adolescents from 16 years of age with a history of hepatitis B viremia while taking lamivudine or with lamivudine resistance mutations: Entecavir 1 mg once daily.
Hepatic impairment: No dose adjustment of Entecavir is required in patients with hepatic impairment.
3. Drug Interactions with Regofa 1
Regofa 1 has been reported to be eliminated mainly by the kidneys, so co-administration of Entecavir with drugs that compete for active tubular secretion or drugs that impair renal function may increase blood levels. of Entecavir or of the drugs used in combination.
Co-administration of Regofa 1 with Lamivudine, Tenofovir disoproxil fumarate or Adefovir dipivoxil did not cause significant drug interactions. Co-administration of Entecavir with drugs that are excreted by the kidneys or known to affect renal function has not been evaluated for adverse effects, therefore patients should be closely monitored for possible effects. harm of Entecavir when it is co-administered with these drugs Lamivudin, Tenofovir disoproxil fumarate or Adefovir dipivoxil.
4. Side effects when taking the drug Regofa 1
During the use of Regofa 1, patients may experience some undesirable side effects that have been reported as follows:
Lactic acidosis Dangerous fatty liver disease Death Hepatitis B becomes severe more important.
5. Pay attention to precautions when using Regofa 1
There have been reports of lactic acidosis, severe hepatomegaly, and death with the use of nucleoside analogues alone or in combination with antiretroviral agents.
There have been reports of a few cases of patients with acute hepatitis B worsening upon discontinuation of anti-hepatitis B therapy, including treatment with Regofa 1. Close monitoring of liver function both clinically and experimentally should continue for at least several months in patients who have discontinued anti-hepatitis B therapy. If appropriate, anti-hepatitis B therapy can be initiated.
Adjustment of the dose of Hepariv is recommended for patients with creatinine clearance < 50 ml/min, including those receiving continuous outpatient peritoneal dialysis (CAPD) or hemodialysis. The safety and effectiveness of Hepariv in liver transplant patients are unknown. If Hepariv treatment is necessary for a liver transplant patient who has been taking certain immunosuppressive drugs that can affect kidney function, such as cyclosporin or tacrolimus, renal function should be checked first and during treatment with Hepariv.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
